1. Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma.
- Author
-
Denlinger, Loren C, Phillips, Brenda R, Sorkness, Ronald L, Bleecker, Eugene R, Castro, Mario, DeBoer, Mark D, Fitzpatrick, Anne M, Hastie, Annette T, Gaffin, Jonathan M, Moore, Wendy C, Peters, Michael C, Peters, Stephen P, Phipatanakul, Wanda, Cardet, Juan Carlos, Erzurum, Serpil C, Fahy, John V, Fajt, Merritt L, Gaston, Benjamin, Levy, Bruce D, Meyers, Deborah A, Ross, Kristie, Teague, W Gerald, Wenzel, Sally E, Woodruff, Prescott G, Zein, Joe, Jarjour, Nizar N, Mauger, David T, and Israel, Elliot
- Subjects
Lung ,Clinical Research ,Asthma ,Respiratory ,Adrenal Cortex Hormones ,Adult ,Aged ,Aged ,80 and over ,Bronchodilator Agents ,Cohort Studies ,Female ,Humans ,Infusions ,Parenteral ,Longitudinal Studies ,Male ,Middle Aged ,Respiratory Function Tests ,Severity of Illness Index ,Treatment Outcome ,severe asthma ,corticosteroid sensitivity ,longitudinal ,lung function ,exacerbations ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: It is unclear why select patients with moderate-to-severe asthma continue to lose lung function despite therapy. We hypothesized that participants with the smallest responses to parenteral corticosteroids have the greatest risk of undergoing a severe decline in lung function.Objectives: To evaluate corticosteroid-response phenotypes as longitudinal predictors of lung decline.Methods: Adults within the NHLBI SARP III (Severe Asthma Research Program III) who had undergone a course of intramuscular triamcinolone at baseline and at ≥2 annual follow-up visits were evaluated. Longitudinal slopes were calculated for each participant's post-bronchodilator FEV1% predicted. Categories of participant FEV1 slope were defined: severe decline, >2% loss/yr; mild decline, >0.5-2.0% loss/yr; no change, 0.5% loss/yr to
- Published
- 2021